Washington Obstetric-Fetal Pharmacology Research Unit

描述（申请人提供）：华盛顿产科药理学研究单位（WOPRU）代表了两所大学和四个医疗中心在国家的国会大厦，是独特的定位，使用人口药代动力学，药代动力学-药效学，临床试验模拟，尖端的体内和体外技术，以评估重要治疗药物的临床药理学及其对孕妇的影响，他们的后代。具体而言，WOPRU将乔治城大学（GU）（牵头机构）和乔治华盛顿大学（GWU）的基础研究资源与MedStar Health（华盛顿医院中心[WHC]和乔治城大学医院[GUH]）、GWU医院和儿童国家医疗中心（CNMC）的临床优势相结合。 我们的医院战略性地分布在整个DC都会区，并与各自的周边社区密切相关。WOPRU的产科医生接生了7 000多名来自不同社会、经济、族裔、种族和文化背景的妇女的婴儿，其中很大一部分怀孕风险很高。WOPRU机构在提供护理和从我们多样化的社区招募患者参加临床试验方面有着良好的记录。 WOPRU的教师代表了一支由高度积极的基础科学家和临床研究人员组成的团队，他们热情地接近成为OPRU新中心的前景。他们是众多基础科学和临床学科的经验丰富的研究人员，在药理学、药效学、药物遗传学、药物代谢、治疗药物监测、蛋白质组学、基因组学和生物统计学方面具有独特的优势，并在多中心临床试验方面拥有丰富的经验。 WOPRU机构的管理层、基础科学和临床研究人员一致渴望支持和参与未来的OPRU网络。

DESCRIPTION (provided by applicant): The Washington Obstetric Pharmacology Research Unit (WOPRU) represents a collaboration among two universities and four medical centers in the nation's capitol that is uniquely positioned to use population pharmacokinetic, pharmacokinetic-pharmacodynamic, clinical trials simulation, cutting edge in vivo and in vitro techniques to assess clinical pharmacology of important therapeutic agents and their effects in pregnant women and their offspring. Specifically, the WOPRU combines the basic research resources of Georgetown University (GU) (lead agency) and George Washington University (GWU) with the clinical strengths of MedStar Health (Washington Hospital Center [WHC] and Georgetown University Hospital [GUH]), GWU Hospital, and Children's National Medical Center (CNMC). Our hospitals are strategically placed throughout the DC metropolitan area, and are closely associated with the respective surrounding communities. The WOPRU obstetricians deliver over 7,000 babies from women who represent a broad spectrum of social, economic, ethnic, racial and cultural backgrounds with a large proportion of these pregnancies being high risk. The WOPRU institutions have an excellent track record of providing care and recruiting patients into clinical trials from our diverse community. The faculty of the WOPRU represent a team of highly motivated basic scientists and clinical investigators who are enthusiastically approaching the prospect of becoming a new center for OPRU. They are experienced investigators in a multitude of basic science and clinical disciplines with a unique combination of strengths in pharmacometrics, pharmacodynamics, pharmacogenetics, drug metabolism, therapeutic drug monitoring, proteomics, genomics and biostatistics in conjunction with significant experience in multi-center clinical trials. The administration, and the basic science and clinical investigators of the WOPRU institutions are unanimous in their eagerness to support and participate in the future OPRU network.